Skip to main content
. 2016 Apr 28;5(7):e1178025. doi: 10.1080/2162402X.2016.1178025

Figure 1.

Figure 1.

CD39 is more expressed in M-CSF-Mφ and TAM from ovarian cancer patients compared to GM-CSF-Mφ (A) The expression of CD39 was analyzed by flow cytometry on GM-CSF-Mφ, M-CSF-Mφ and TAM isolated from patients. Results are expressed in relative fluorescent intensity (RFI values are the ratio of antibody/isotype control antibody) (mean ± SEM, n = 11 for M-CSF-Mφ, GM-CSF-Mφ and n = 5 for TAM), *p < 0 .05 compared to GM-CSF-Mφ (B) M-CSF-Mφ polarization results in the acquisition of CD39 expression whereas GM-CSF-Mφ polarization results in its maintenance. CD39 expression was analyzed by flow cytometry. Results are expressed in RFI values, as mean ± SEM (n = 4 for monocytes, n = 11 for GM-CSF-Mφ and n = 11 for M-CSF-Mφ). (C) HPLC analysis of Etheno-ATP (ATP), -ADP (ADP), -AMP (AMP) and -adenosine (Ado) are expressed in percentage compared to the initial dose of ATP (200 µM = 100%) during 20 min. in GM-CSF-Mφ and M-CSF-Mφ (mean of two representative donors). In certain conditions, CD39 inhibitor (POM-1) was used at 10 µM.